Review
Published · Updated · 1 min read
Interleukin assays: specialized use rather than routine testing
What it means for practice
Consider interleukin assays in specialized clinical settings rather than as routine tests. The review highlights IL-6 in cytokine release syndrome and severe COVID-19, and sIL-2R in hemophagocytic lymphohistiocytosis.
Summary
This review addresses the clinical use of interleukin assays in inflammatory, autoimmune, and infectious diseases. It focuses on interleukin 6 (IL-6), interleukin 1β (IL-1β), and soluble interleukin 2 receptor (sIL-2R). According to the supplied abstract, routine use of these assays remains limited.
Clinical relevance
The review discusses validated indications, clinical thresholds, and analytical limitations. It specifically highlights the utility of IL-6 in cytokine release syndrome and severe COVID-19. Measurement of sIL-2R is identified as important in hemophagocytic lymphohistiocytosis. IL-1β is also among the main markers reviewed, but the abstract does not give a specific clinical indication for it.
Limitations and practical conclusion
High costs and assay variability limit routine use. The review suggests using these tests primarily in specialized settings. The abstract provides no specific thresholds or quantitative measures of diagnostic accuracy, so it does not support defining clinical decision criteria from these measures.
Source
-
Dosage des interleukines en pratique clinique : état des lieux pour le clinicien.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
